Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | CCNC | P24863 | 3/20 | 0.40 |
| ▸ | CDK8 | P49336 | 3/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248682 | 0.76 | DRD4 (0.52) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL7242612 | 0.75 | DRD4 (0.51) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL13085158 | 0.75 | DRD2 (0.50) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL7091310 | 0.71 | CCNC (0.50) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL15104852 | 0.68 | CCNC (0.47) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL2831893 | 0.67 | DRD2 (0.47) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL8027345 | 0.64 | DRD4 (1.00) | DRD2DRD4CCNCCDK8CDK19 | |
| Hydrochloric Acid SCHEMBL8022012 | 0.63 | DRD4 (0.97) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL21614788 | 0.62 | DRD2 (0.49) | DRD2DRD4CCNCCDK8CDK19 | |
| SCHEMBL9212631 | 0.61 | DRD4 (0.55) | DRD2DRD4CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | DRD2 616/4885DRD4 567/4885CCNC 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.